Chai Discovery raises $400M for AI drug design at $3.8B valuation
The San Francisco startup says it will use the cash to expand its AI models for designing new medicines after deals with Pfizer and Lilly.
Chai Discovery raised $400 million on July 14, valuing the company at $3.8 billion. The startup has struck agreements with Pfizer, Novartis, and Eli Lilly for its antibody-design software.

